Please login to the form below
Compassionate use programme
This page shows the latest Compassionate use programme news and features for those working in and with pharma, biotech and healthcare.
Novartis pulls out of Mesoblast deal
The phase 3 trial in question was initiated after very positive results from an open-label compassionate use programme that suggested remestemcel-L offered an 83% survival rate in patients on ... use data from a single-arm, open-label study rather than a
Latest news
-
Biogen to open compassionate use programme for ALS patients with ‘rapidly progressive disease’
Biogen is aiming to start offering compassionate use access to a subset of SOD1-ALS patients with the ‘most rapidly progressive disease’ after patients in the late-stage study on placebo ... Following this, if the results from the phase 3 study show
-
WHO trial casts doubt on remdesivir's efficacy
Gilead also revealed analyses from its compassionate use programme, which demonstrated that 83% of paediatric patients and 92% of pregnant and postpartum women with a broad spectrum of disease severity recovered ... Regeneron also recently announced that
-
Gilead reports remdesivir cuts risk of death in severe COVID-19 patients
Also reveals new analyses from compassionate use programme. In new data released detailing the efficacy of Gilead’s investigational antiviral remdesivir, the drug reduced the risk of death by 62% in ... Gilead also revealed new analyses from its
-
Mesoblast expands compassionate use COVID-19 programme
Will now include children with multisystem inflammatory syndrome. Australian-based regenerative medicine company Mesoblast has expanded access to its compassionate use programme in the US of its investigational candidate to include
-
AbbVie suspends Kaletra patent rights as COVID-19 drug trials advance
Other potential drug treatments for COVID-19 include anti-inflammatories, such as Roche’s Actemra(tocilizumab) which was recently approved for use in severely-ill coronavirus patients with elevated IL-6 ... levels. Looking to join Roche and a number of
More from news
Approximately 1 fully matching, plus 17 partially matching documents found.
Latest Intelligence
-
As COVID-19 takes over the world, biopharma fights back
compassionate use requests for the drug following an overwhelming demand for the drug. ... Although the compassionate use programme now only extends to children and pregnant women, Gilead said the ‘expanded access’ programme will allow hospitals or
-
The Cystic Fibrosis Buyers’ Club
Just Treatment is also urging the UK government to override Vertex’s patent via compulsory licensing or Crown Use Licence. ... It also stressed that it is continuing to provide free medicines to the most seriously ill patients through its compassionate
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Innovative Trials
Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ of experience, Innovative Trials deploys...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
